223 related articles for article (PubMed ID: 2509416)
21. [Antimicrobial activity of carbapenems and the combined effect with aminoglycoside against recent clinical isolates of Pseudomonas aeruginosa].
Tasaka K; Ishida A; Chinzei T
Jpn J Antibiot; 2002 Apr; 55(2):181-6. PubMed ID: 12071095
[TBL] [Abstract][Full Text] [Related]
22. In vitro activity and killing effect of DX-8739, a new carbapenem, compared with those of meropenem and imipenem against multiresistant Pseudomonas aeruginosa.
Giamarellos-Bourboulis EJ; Grecka P; Giamarellou H
Antimicrob Agents Chemother; 1995 Mar; 39(3):731-4. PubMed ID: 7793881
[TBL] [Abstract][Full Text] [Related]
23. Synergy of imipenem--a novel carbapenem, and rifampin and ciprofloxacin against Pseudomonas aeruginosa, Serratia marcescens and Enterobacter species.
Chin NX; Neu HC
Chemotherapy; 1987; 33(3):183-8. PubMed ID: 3109815
[TBL] [Abstract][Full Text] [Related]
24. In vitro and in vivo antibacterial activities of meropenem, a new carbapenem antibiotic.
Harabe E; Kawai Y; Kanazawa K; Otsuki M; Nishino T
Drugs Exp Clin Res; 1992; 18(2):37-46. PubMed ID: 1644010
[TBL] [Abstract][Full Text] [Related]
25. Antibacterial properties of meropenem towards clinical isolates, beta-lactamase producers and laboratory mutants.
Wiedemann B; Zühlsdorf M
J Antimicrob Chemother; 1989 Sep; 24 Suppl A():197-205. PubMed ID: 2681124
[TBL] [Abstract][Full Text] [Related]
26. Postantibiotic effect of imipenem, alone and in combination with amikacin, on Pseudomonas aeruginosa.
Gerçeker AA; Otük G
Chemotherapy; 1995; 41(6):433-6. PubMed ID: 8529433
[TBL] [Abstract][Full Text] [Related]
27. Comparison of in vitro activity of doripenem, imipenem and meropenem against clinical isolates of Enterobacteriaceae, Pseudomonas and Acinetobacter in Southern Poland.
Drzewiecki A; Bulanda M; Talaga K; Sodo A; Adamski P
Pol Przegl Chir; 2012 Sep; 84(9):449-53. PubMed ID: 23241660
[TBL] [Abstract][Full Text] [Related]
28. Isolation and in-vitro and in-vivo characterisation of a mutant of Pseudomonas aeruginosa PAO1 that exhibited a reduced postantibiotic effect in response to imipenem.
Majcherczyk PA; Kunz S; Hattenberger M; Vaxelaire J; Zak O; O'Reilly T
J Antimicrob Chemother; 1994 Oct; 34(4):485-505. PubMed ID: 7646646
[TBL] [Abstract][Full Text] [Related]
29. Comparative Activity of Carbapenem Testing (COMPACT) study in Germany.
Valenza G; Seifert H; Decker-Burgard S; Laeuffer J; Morrissey I; Mutters R;
Int J Antimicrob Agents; 2012 Mar; 39(3):255-8. PubMed ID: 22230334
[TBL] [Abstract][Full Text] [Related]
30. [Comparative activity of doripenem, meropenem, and imipenem in recent clinical isolates obtained during the COMPACT-Spain epidemiological surveillance study].
Gimeno C; Cantón R; García A; Gobernado M;
Rev Esp Quimioter; 2010 Sep; 23(3):144-52. PubMed ID: 20844845
[TBL] [Abstract][Full Text] [Related]
31. The antibacterial activity of meropenem in combination with gentamicin or vancomycin.
Wise R; Ashby JP; Andrews JM
J Antimicrob Chemother; 1989 Sep; 24 Suppl A():233-8. PubMed ID: 2509417
[TBL] [Abstract][Full Text] [Related]
32. [Comparative evaluation of in vitro activities of carbapenems against gram-negative pathogens: Turkish data of COMPACT study].
Korten V; Söyletir G; Yalçın AN; Oğünç D; Dokuzoğuz B; Esener H; Ulusoy S; Tünger A; Aygen B; Sümerkan B; Arman D; Dizbay M; Akova M; Hasçelik G; Eraksoy H; Başaran S; Köksal I; Bayramoğlu G; Akalın H; Sınırtaş M
Mikrobiyol Bul; 2011 Apr; 45(2):197-209. PubMed ID: 21644063
[TBL] [Abstract][Full Text] [Related]
33. Comparative activity of meropenem against Pseudomonas aeruginosa strains with well-characterized resistance mechanisms.
Livermore DM; Yang YJ
J Antimicrob Chemother; 1989 Sep; 24 Suppl A():149-59. PubMed ID: 2553657
[TBL] [Abstract][Full Text] [Related]
34. Influence on Enterobacter cloacae metabolism, cell-surface hydrophobicity and motility of suprainhibitory concentrations of carbapenems.
Majtán V; Majtánová L
Folia Microbiol (Praha); 2001; 46(6):505-10. PubMed ID: 11898339
[TBL] [Abstract][Full Text] [Related]
35. In vitro activity of meropenem, imipenem, cefepime and ceftazidime against Pseudomonas aeruginosa isolates from cystic fibrosis patients.
Christenson JC; Korgenski EK; Daly JA
J Antimicrob Chemother; 2000 Jun; 45(6):899-901. PubMed ID: 10837448
[TBL] [Abstract][Full Text] [Related]
36. In vitro activity of newer broad spectrum beta-lactam antibiotics against enterobacteriaceae and non-fermenters: a report from Austrian intensive care units. Austrian Carbapenem Susceptibility Surveillance Group.
Krause R; Mittermayer H; Feierl G; Allerberger F; Wendelin I; Hirschl A; Reisinger EC
Wien Klin Wochenschr; 1999 Jul; 111(14):549-54. PubMed ID: 10467641
[TBL] [Abstract][Full Text] [Related]
37. Comparative in vitro pharmacodynamics of imipenem and meropenem against ATCC strains of Escherichia coli, Staphylococcus aureus and Bacteroides fragilis.
White RL; Friedrich LV; Manduru M; Mihm LB; Bosso JA
Diagn Microbiol Infect Dis; 2001 Jan; 39(1):39-47. PubMed ID: 11173190
[TBL] [Abstract][Full Text] [Related]
38. Comparative in vitro antimicrobial activity of a new carbapenem, E1010, and tentative disc diffusion test interpretative criteria.
Fuchs PC; Barry AL; Brown SD
J Antimicrob Chemother; 2001 Jul; 48(1):23-8. PubMed ID: 11418509
[TBL] [Abstract][Full Text] [Related]
39. Postantibiotic effects of imipenem, norfloxacin, and amikacin in vitro and in vivo.
Renneberg J; Walder M
Antimicrob Agents Chemother; 1989 Oct; 33(10):1714-20. PubMed ID: 2511798
[TBL] [Abstract][Full Text] [Related]
40. In vivo and in vitro study of several pharmacodynamic effects of meropenem.
Fuentes F; Martín MM; Izquierdo J; Gomez-Lus ML; Prieto J
Scand J Infect Dis; 1995; 27(5):469-74. PubMed ID: 8588137
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
